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A B S T R A C T
The aim of the study was to determine additional risk factors that could increase the prevalence of hepatitis C (HCV)
infection among injecting drug users (IDU). The study included 327 heroin addicts registered in Zadar County, Croatia.
The participants were divided into two groups according to their HCV status. HCV-positive and HCV-negative study par-
ticipants were compared. HCV-positive group started injecting heroin at earlier age (median 18.5 years) than HCV-nega-
tive group (median 20.0 years) (p=0.032) and had been injecting heroin for a significantly longer period (median 5 years
vs. median 4 years, respectively; p<0.001). IDUs in HCV-positive group shared their injecting equipment significantly
more often than IDUs in HCV-negative group (p<0.001; c2=32.7). The main reasons for starting drugs were curiosity,
psychological reasons (depression and/or neurosis), and peer or partner pressure in HCV-positive group, and fun, curios-
ity, and peer pressure in HCV-negative group (p=0.051; c2=23.6). Earlier onset of heroin use, longer heroin use, sharing
injection equipment, curiosity, and psychological problems as reasons for starting drugs were associated with higher
prevalence of HCV infection among injecting heroin users in Zadar County.
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Introduction
Shortly after it was discovered in 1989, hepatitis C vi-
rus (HCV) was recognized as the main cause of chronic
liver disease. The World Health Organization (WHO) es-
timates that the prevalence of HCV infection is 2%, i.e.
123 million people in the world are infected with HCV1.
Between 75% and 85% of population with acute HCV in-
fection develops chronic hepatitis C with or without in-
crease in alanine aminotransferase (ALT) blood levels2,3.
Within 10–20 years, 8–25% of these patients develop
liver cirrhosis4 with a risk of liver damage, hepatocellular
cancer, and death from liver disease5,6.
In developed countries, HCV is primarily transmitted
by injection drug use. The prevalence of HCV infection
among injecting drug users (IDUs) who have injected
drugs for six or more years is between 64% and 94%7–10.
In Croatia, the number of opiate users is around 13,000
(2.7/1000 population). If we assume that 70–85% of IDUs
in Croatia are positive to anti-HCV, then their number
ranges between 9100 and 11,05011.
Although drug use is more frequent in population of
low socioeconomic status, a direct association between
drug addiction and socioeconomic status has not been
proven12. Many studies have shown that the increased
incidence of HCV infection among IDUs is associated
with higher frequency of drug injection13–16. The risk of
exposure to HCV infection increases with the number of
episodes of drug use17. Also, IDUs who share injection
equipment are at greater risk of acquiring HCV infec-
tion18,19. Most IDUs come from a low socioeconomic back-
ground and live with their parents or family20. Although
many risk factors for HCV infection in IDUs are known,
there could be additional factors that have not yet been
investigated. In the context of high prevalence and in-
creasing incidence of injecting drug use, research into
the characteristics of IDUs could contribute to early rec-
ognition of those at risk of HCV infection and improve
the implementation of preventive and therapeutic mea-
sures.
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The aim of our study was to determine additional risk
factors associated with HCV infection in IDUs in Zadar
County, Croatia.
Subjects and Methods
The questionnaire study was conducted among 421
current and former injecting drug users registered at the
Center for Prevention and Outpatient Treatment of Ad-
diction in Zadar, Croatia, between January 1, 2001 and
January 1, 2005. The participation in the study was vol-
untary. IDUs who agreed to participate were asked to un-
dergo testing for hepatitis C and B infection. Ninety-four
registered IDUs were excluded from the study because
they either refused testing or did not answer all the ques-
tions in the questionnaire. The final sample consisted of
327 IDUs with complete questionnaires and available
HCV and HBV test results. There were 272 (83.2%) men
and 55 (16.8%) women aged between 17 and 51 years
(Table 1). Based on their HCV-serology results, they were
divided into HCV-positive and HCV-negative group and
compared by age, duration of heroin use, practice of in-
jection equipment sharing, age of onset of drug use, and
motives to start using drugs as key risk factors for HCV
infection.
Questionnaire
IDUs were asked to complete the questionnaire dur-
ing their regular visits to the Center. A physician or psy-
chologists working at the Center helped them fill in the
data. The questionnaire has been in standard use in
Croatia since 1990. It is based on the Treatment Demand
Indicator Protocol21, a standard questionnaire developed
by the European Center for Monitoring of Drugs and
Drug Addiction and Pompidou group (http://www.coe.int/
T/dg3/pompidou/default_en.asp). This questionnaire is
used to collect uniform data on drug users in the treat-
ment programs in over 35 European countries. The ques-
tionnaire consists of 11 sections covering the following
areas: drug addiction treatment, sociodemographic back-
ground, drug abuse, risk behavior, other treatment, fam-
ily data, legal issues, previous addiction history, health
problems, causes of drug abuse, and confidential per-
sonal data (Appendix). The section on health problems
includes information on the IDU’s HCV and HBV status,
which is provided by a physician after IDU’s HCV and
HBV testing results become available.
Testing for HCV infection
After IDUs completed the questionnaire, they were
referred to the Department of Transfusion Medicine of
Zadar General Hospital for blood sampling and HCV and
HBV testing. Serum HCV and HBV antibodies were de-
termined on the same day. Anti-HCV was determined
with a highly sensitive microparticle enzyme immuno-
assay AxSYM HCV, version 3.0 (ABBOTT, Wiesbaden,
Germany). The third generation of microparticle enzyme
immunoassay (ABBOTT) AxSYM HBsAg(V2) was used
to determine serum HBsAg.
Statistical analysis
Numerical data were tested for normal distribution
by Kolmogorov-Smirnov test and presented as mean val-
ues with standard deviation (± SD) or median with range.
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TABLE 1
CHARACTERISTICS OF INJECTING DRUG USERS (IDUS) WITH AND WITHOUT HEPATITIS C VIRUS (HCV) INFECTION, REGISTERED
AT ZADAR CENTER FOR PREVENTION AND OUTPATIENT TREATMENT OF ADDICTION
Characteristic
No. (%) of IDUs
p
HCV positive (n=193) HCV negative (n=134)
Age (years; median, range) 28 (18–51) 26 (17–48) 0.004*
Sex (m/f) 164/29 108/26 0.298†
Education level: N/A
elementary 23 (11.9) 10 (7.5)
high school 164 (85.0) 112 (83.6)
college or university 4 (2.1) 9 (6.7)
unknown 2 (1.0) 3 (2.2)
Socioeconomic level (EUR per month) 0.457†
low (<400) 74 (38.3) 41 (30.6)
middle (400–800) 103 (53.4) 77 (57.5)
high (>800) 16 (8.3) 12 (9.0)
Unknown (missing data) 0 4 (3.0)
Age of first-time heroin use (years; median, range) 18.5 (13.0–40.0) 20.0 (13.0–43.0) 0.032*
Age of first-time use of any drug (years; median, range) 16.0 (10.0–40.0) 16.0 (12.0–41.0) 0.628*
Total duration of heroin use (years; median, range) 5.0 (1.0–20.0) 4.0 (1.0–20.0) 0.001*
*Mann-Whitney test, †c² test.
Variables that were not normally distributed or variables
without homogeneous variance were compared using
non-parametric Mann-Whitney test. Qualitative data
were compared with either c2-test or Fisher’s exact test,
as appropriate. Logistic regression was used to assess
multivariate prediction of HCV infection, which was pre-
sented as odds ratio (OR) with 95% confidence intervals
(95% CI). All statistical analyses were performed with
SAS System for Windows, release 8.02 (SAS Institute
Inc., Cary, NC, USA) and p<0.05 was considered statisti-
cally significant.
Results
The HCV-positive group consisted of 193 IDUs, and
HCV-negative group consisted of 134 IDUs. Men-to-wo-
men ratio was 5:1 in both groups. The groups did not dif-
fer in education level and economic status of their fami-
lies (Table 1). Although the median age of first use of any
drug was 16 years in both groups, HCV-positive IDUs
started using heroin at a significantly younger age than
HCV-negative IDUs and had used it for a longer time.
Also, HCV-positive IDUs were significantly older than
HCV-negative IDUs at the time of the study (Table 1).
The median duration of heroin use in HCV-positive group
was 5 years (range, 1–20), which was significantly longer
than the 4-year median duration of heroin use in the
HCV-negative group (range, 1–20) (p<0.001; Mann-Whit-
ney test).
HBV monoinfection was found in only 6 (4.5%) IDUs,
whereas the serologic markers of HBV-HCV coinfection
were detected in 55 (16.8%) of them.
In comparison with HCV-negative IDUs, HCV-posi-
tive IDUs shared their injecting drug equipment signifi-
cantly more often (Table 2). They were also coinfected
with HBV significantly more often than HCV-negative
IDUs (Table 3).
IDUs were asked to choose the three most important
reasons for starting experimenting with drugs from the
following list: self-confirmation (showing off), influence
of peers or partner, family problems, problems at school,
psychological reasons (depression, neurosis, or adoles-
cent insecurity), boredom, fun, curiosity, unawareness of
any possible negative consequences, or unknown. Some
of these motives were more frequent among HCV-posi-
tive IDUs, whereas others were more frequent among
HCV-negative users (Table 4). In HCV-positive groups,
curiosity was selected as the most common reason, fol-
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TABLE 2
DISTRIBUTION OF INJECTING DRUG USERS (IDUS) INCLUDED
IN THE STUDY WITH RESPECT TO INJECTION EQUIPMENT
SHARING
Sharing
injection
equipment
No. (%) of IDUs*
HCV positive
(n=193)
HCV negative
(n=134)
total
(n=327)
yes 183 (94.8) 72 (53.7) 255 (78.0)
no 10 (5.2) 62 (46.3) 72 (22.0)
*p<0.001; c2 test.
TABLE 3
DISTRIBUTION OF INJECTING DRUG USERS (IDUS) INCLUDED
IN THE STUDY WITH RESPECT TO THE PRESENCE OF
HEPATITIS B (HBV) AND HEPATITIS C (HCV) INFECTION
HBV
infection
No. (%) of IDUs*
HCV positive
(n=193)
HCV negative
(n=134)
total
(n=327)
yes 55 (28.5) 6 (4.5) 61 (18.6)
no 138 (71.5) 128 (95.5) 266 (81.4)
*p<0.001; c2t est.
TABLE 4
DISTRIBUTION OF INJECTING DRUG USERS (IDUS) INCLUDED IN THE STUDY WITH RESPECT TO THE ONSET
OF EXPERIMENTING WITH DRUGS
Motive for experimenting
No (%) of IDUs
HCV positive HCV negative total
Wish for self-confirmation 19 (9.8) 9 (6.7) 28 (8.6)
Peer or partner pressure 34 (17.6) 21 (15.7) 55 (16.8)
Family problems 12 (6.2) 7 (5.2) 19 (5.8)
Problems at school 1 (0.5) 0 1 (0.3)
Psychological reasons 34 (17.6) 16 (11.9) 50 (15.3)
Boredom 23 (11.9) 12 (9.0) 35 (10.7)
Fun 15 (7.8) 30 (22.4) 45 (13.8)
Curiosity 50 (25.9) 29 (21.6) 79 (24.2)
Lack of knowledge about possible
negative consequences
5 (2.6) 6 (4.5) 11 (3.4)
Unknown 0 4 (3.0) 4 (1.2)
Total 193 (100.0) 134 (100.0) 327 (100.0)
lowed by psychological reasons and peer- or partner-
-pressure. In HCV-negative groups, the top three reasons
for starting experimenting with drugs in the order of fre-
quency were fun, curiosity, and peer- or partner-pressure
(Table 4).
The predictors of HCV infection included in the logis-
tic regression model were age of onset of intravenous
heroin use, duration of intravenous heroin use, sharing
injecting equipment, and motives to start experimenting
with drugs. The result showed that sharing injection
equipment and duration of intravenous heroin use were
the significant predictors of HCV infection (Table 5).
Odds ratio point estimate for sharing injection equip-
ment was 13.284 (95% CI = 4.957–35.601), showing that
IDUs who shared their injecting equipment were over 13
times more likely to acquire HCV infection. The model
was statistically significant (–2 log likelihood 280.803,
c²12= 65.466, p<0.001), and its predictive accuracy was
74.9%.
Discussion
We found that IDUs positive to HCV infection had
started injecting heroin at younger age, used it for a lon-
ger time, and shared their drug injection equipment
more often than HCV-negative IDUs. The main finding
was that they were significantly younger than HCV-neg-
ative IDUs. The combination of these factors could be the
main risk for acquiring HCV infection. It has been found
that early onset of heroin use increases the risk of both
addiction and HCV infection22. In comparison with the
experienced (registered) IDUs, young IDUs were found
to be at higher risk of blood-borne infections because of
their high-risk behavior pattern18,23. Young IDUs are
usually less critical toward drugs, less cautious, and
more easily influenced by others, therefore more exposed
to HCV infection13,24. Also, young IDUs share their drug
equipment more readily than older IDUs25,26. The possi-
bility of HCV transmission via additional injection equip-
ment, such as cotton swabs or water, is often underesti-
mated, as well as the nature of social relationships among
IDUs characterized by unlimited mutual trust. Young
IDUs also know less about HCV infection and its trans-
mission pattern. Furthermore, they have occasional or
convenient sex more often, and are frequently involved
in sex industry (prostitution), while at the same time
they rarely use condoms26–28 and easily agree to inject
drugs29. This knowledge is valuable to the professionals
working on the prevention of drug use among youth, as
they can use it for the development of guidelines for
timely health-care interventions, including dispensing
sterile injection equipment13.
The methods for prevention of HCV infection are the
same as methods for prevention of HIV infection. A study
among young HIV-positive drug users found that 88% of
them had coinfection with HCV, showing that HCV-HIV
coinfection is almost as frequent among drug users as
HIV infection alone13. However, prevention is possible. It
was shown that having a safe place for injecting drugs
was successful in reducing the HIV and HCV infection
incidence among young IDUs22.
Age of diagnosis of HCV infection plays an important
role in the guidelines for antiviral treatment and its
outcome2. In young IDUs, HCV seroconversion occurs
early, HCV mortality is high (even without cirrhosis), the
infection is reversible after re-exposure despite success-
ful antiviral treatment30,31. Therefore, it is important to
identify IDUs and HCV infection as early as possible.
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TABLE 5
LOGISTIC REGRESSION ANALYSIS OF PREDICTORS OF INJECTING DRUG USE*
Predictors b (SE) p OR (95% CI)
Age of onset of drug use 0.009 (0.034) 0.786 1.009 (0.944–1.080)
Duration of drug use 0.130 (08.042) 0.002 1.138 (1.049–1.236)
Sharing injection equipment 2.587 (0503) <0.001 13.284 (4.957–35.601)
Motives for experimenting with drugs 0.144
self-confirmation 6.939 (22.247) 0.755 1031.529 (0.000–8.92E+21)
peer or partner pressure 7.386 (22.245) 0.740 1612.481 (0.000–1.39E+22)
family problems 6.886 (22.249) 0.757 978.890 (0.000–8.49E+21)
problems in school 11.122 (31.454) 0.724 67612.102 (0.000–4.02E+31)
psychological reasons 7.162 (22.244) 0.747 1289.306 (0.000–1.11E+22)
boredom 7.084 (22.244) 0.750 1192.441 (0.000–1.03E+22)
fun 5.648 (22.243) 0.800 283.727 (0.000–2.43E+21)
curiosity 6.690 (22.242) 0.764 804.070 (0.000–6.88E+21)
lack of knowledge about adverse
consequences of drug use
6.157 (22.252) 0.782 472.043 (0.000–4.12E+21)
Constant –9.204 (22.256) 0.679
*Abbreviati: SE – standard error of b; OR – odds ratio; CI – confidence interval.ons
Most IDUs in our study were men. Men are more of-
ten in contact with drugs and more prone to experiment
with drugs22,32.
Lower socioeconomic background and lower educa-
tion level are believed to be important factors for higher
prevalence of HCV infection33,34. In our study, however,
most IDUs had an average living standard, whereas
those belonging to higher socioeconomic class were rare.
Our results showed that the longer the heroin use,
the higher the risk of HCV infection. The risk of HCV in-
fection doubles every 2 years of continuous heroin use;
after 6 or more years of continuous use, it is 10-fold
higher13. In our study, HCV positive IDUs were older
than HCV-negative ones, which shows that age and the
duration of drug use should be considered mutually asso-
ciated factors influencing the occurrence of HCV in-
fection10,13,18,30,35–38.
Sharing injection equipment is one of the most impor-
tant factors for HCV transmission13–16. HCV-positive
group shared their equipment with other drug users sig-
nificantly more often than HCV-negative group. HCV in-
fection is not transmitted only by sharing needles, but
also by sharing cotton swabs and other equipment15,31,39,40.
In our study, we considered that drug injection equip-
ment was shared if any of the equipment items were
shared.
The incidence of HCV infection significantly decre-
ased, especially among young IDUs, after the needle/ sy-
ringe exchange program has been introduced41. Reduced
spread of HCV and other blood-borne diseases can also
be achieved by better health education of population and
implementation of law enforcement measures against
drugs and drug use42.
HCV infection is closely associated with HBV infec-
tion as the viruses share the same transmission route
(blood and sexual intercourse)43. In our study, over a
quarter of IDUs with HCV infection were HBsAg posi-
tive. This is important for the prognosis of HCV infec-
tion, as the risk of serious liver disease (cirrhosis or liver
cancer) increases in patients with coinfection in compari-
son with those who have only HCV infection44,45.
Motives to start experimenting with drugs differed
between HCV-positive and HCV-negative IDUs in our
study. Although family was selected as the most impor-
tant reason, followed by school problems, peer pressure,
media, and society in general46, family problems were not
high on the list of reasons. Parental acceptance or rejec-
tion was not an important reason either12. Fun and curi-
osity, followed by peer or partner pressure were the pri-
mary reasons to start using drugs in our sample of HCV
negative IDUs. This showed that HCV-positive and HCV-
-negative IDUs had different attitudes toward drugs and
drug use from the start. HCV-negative IDUs also seemed
to be less open to the influence of microsocial environ-
ment, which could explain their lower risk of HCV infec-
tion.
Possible limitation of our study could be the fact that
almost a quarter of IDUs registered at the Center re-
fused testing or omitted to complete the questionnaire.
Despite this possible exclusion bias, our results were sim-
ilar to previous findings. Further research should look
more thoroughly into risk factors for drug abuse and
blood-borne infections among adolescents, when drug
abuse usually starts12. Primary measures for drug abuse
prevention should primarily target teenagers. Health ed-
ucation and injection equipment exchange programs are
presently the only means of control of HCV infection
spread among IDUs19. We should increase our under-
standing of HCV epidemiology within individual risk
groups, predict the points of timely prevention, and
choose the most effective time and manner to educate
children and adolescents (senior elementary school) about
the risks and consequences of drug use. Public health ac-
tions should target IDUs directly, especially the young
ones, who are at highest risk of developing the addiction.
The possibility to get in contact and start experimenting
with drugs should be limited and use of hard drugs post-
poned as much as possible to older age, as it is known
that the risk of HCV infection and addiction decreases
with age and treatment is easier to implement and usu-
ally more successful. According to the evidence so far, the
risk of HCV infection can certainly be reduced with the
decrease in the number of IDUs.
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KARAKTERISTIKE HEPATITIS C INFEKCIJE IZME\U INTRAVENSKIH OVISNIKA
U ZADARSKOJ @UPANIJI
S A @ E T A K
Cilj ove studije je odrediti dodatne faktore rizika koji mogu pove}ati prevalenciju hepatitisa C (HCV) me|u intraven-
skim ovisnicima (IV ovisnici). Studija uklju~uje 327 heroinskih ovisnika u Zadarskoj `upaniji, Hrvatska. Sudionici su
podijeljeni u dvije grupe prema HCV statusu. HCV-pozitivni i HCV-negativni sudionici su uspore|ivani. HCV-pozitivni
ovisnici ranije po~inju koristiti heroin venskim putem (median 18,5 godina) u odnosu na HCV-negativne (median 20.0
godina) (p=0,032) i du`e konzumiraju heroin (median 5 godina; median 4 godine, uzastopce; p<0,001). IV ovisnici HCV
pozitivnoj grupi ~e{}e se dijele pribor za drogiranje od HCV-negativnih ovisnika (p<0,001: c2=32.7). Glavni razlozi za
po~etak konzumiranja droga u HCV-pozitivnih ovisnika su znati`elja, psiholo{ki razlozi (depresija, neuroza), te utjecaj
partnera ili vr{njaka, dok su u HCV-negativnih ovisnika zabava, znati`elja, te utjecaj partnera ili vr{njaka (p=0,051;
c2=23,6). Ranije uzimanje heroina, du`e uzimanje heroina, dijeljenje zajedni~kog pribora, znati`elja i psiholo{ki pro-
blemi su razlozi povezani sa visokom prevalencijom HCV infekcije me|u intavenskim ovisnicima u Zadarskoj `upaniji.
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